natgillin/translations-raw huggingface dataset:
Some patients may develop antibodies (a type of protein produced by the body) to somatropin.
Pri nekaterih bolnikih se lahko razvijejo protitelesa (vrsta beljakovine, ki jo proizvaja telo) proti somatropinu.
Avoid areas of extreme temperature.
Izogibajte se predelom s skrajnimi temperaturami.
Do not shake vigorously as it could denature the protein.
Ne stresajte močno, da ne boste denaturirali beljakovine.
• If your pen requires cleaning, do not place under water.
• Če je injekcijski peresnik potreben čiščenja, ga ne dajajte v vodo.
For further information ask your doctor.
Za dodatne informacije se posvetujte z zdravnikom.
This results in a measurable increase in body length until these growth plates fuse at the end of puberty.
Posledica je merljivo zvečanje telesne višine, dokler se ploščice na koncu pubertete ne zaprejo.
In older or overweight patients, lower doses may be necessary.
Pri starejših bolnikih in bolnikih s prekomerno telesno maso utegnejo biti potrebni manjši odmerki.
If you experience any of these symptoms, you should inform your doctor.
Če opazite katerega od teh simptomov, morate o tem obvestiti svojega zdravnika.
For instructions for use and handling of the medicinal product, see section 6.6.
Za navodila za pripravo in ravnanje z zdravilom glejte poglavje 6.6.
Q: What should I do if there is not enough solution left in the cartridge for my next dose?
V: Kaj naj naredim, če v vložku ni več dovolj zdravila za odmerek, ki ga potrebujem?
IGF-I levels, which were low at study entry, were restored to within the normal range with somatropin therapy.
Vrednosti IGF-I, ki so bile nizke ob vstopu v študijo, so se po zdravljenju s somatropinom vrnile v normalne vrednosti.
Chemical and physical in-use stability has been demonstrated for 28 days at 2°C - 8°C.
Kemična in fizikalna stabilnost med uporabo sta dokazani za 28 dni pri temperaturi 2 °C - 8 °C.
This means that there is a risk that women, especially those on oral oestrogen therapy, are undertreated while men are over-treated.
To pomeni, da pri ženskah, še posebej tistih, ki se zdravijo s peroralnimi estrogeni, obstaja tveganje za nezadostno zdravljenje, pri moških pa za prekomerno zdravljenje.
Long-term overdose could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess growth hormone.
Dolgoročno preveliko odmerjanje bi lahko povzročilo simptome in znake gigantizma in/ali akromegalije, kot so znani pri presežku rastnega hormona.
Q: Is it possible to turn the black dose knob back if I click too many times?
V: Lahko črni odmerni gumb zasučem nazaj, če ga zavrtim za preveč klikov?
Always store the pen and cartridges in a clean, safe place in the refrigerator at a temperature between 2-8°C and out of children's reach and sight.
Injekcijski peresnik in vložke vedno shranjujte na čistem, varnem mestu v hladilniku, pri temperaturi 2 °C - 8 °C in nedosegljive otrokom.
Cell growth: Treatment with somatropin results in an increase in both the number and size of skeletal muscle cells.
Rast celic: Zdravljenje s somatropinom zveča število in velikost skeletnih mišičnih celic.
Shown below are the items necessary for giving an injection.
Spodaj so narisani deli, potrebni za injiciranje.
Therefore, the benefit-risk assessment for continuing treatment should be performed carefully.
Zato je treba oceno koristi in tveganja nadaljnjega zdravljenja skrbno pretehtati.
Psychiatric disorders Uncommon: Personality disorder
Psihiatrične motnje Občasni: osebnostna motnja
A total of 58% and 65% of somatropin-treated patients, who were below normal range at baseline, had reached heights within the normal range by Month 24.
Skupno 58 % in 65 % bolnikov, ki so se zdravili s somatropinom, in so v izhodišču imeli telesno višino, manjšo od normalne, je v 24. mesecu doseglo telesno višino v mejah normale.
The data on growth rate and height SDS were broadly similar to those observed in the pivotal studies.
Podatki o stopnji rasti in vrednosti SDS telesne višine so v veliki meri podobni podatkom iz ključnih študij.
A small percentage of patients may develop antibodies to the protein somatropin.
Pri majhnem odstotku bolnikov se lahko razvijejo protitelesa proti beljakovini somatropinu.
• If you have Prader-Willi syndrome, you should not be treated with NutropinAq unless you have growth hormone deficiency.
• Če imate Prader-Willijev sindrom, se ne smete zdraviti z zdravilom NutropinAq, razen če imate pomanjkanje rastnega hormona.
There are no or limited data from the use of somatropin in pregnant women.
Podatkov o uporabi somatropina pri nosečnicah ni oziroma so omejeni.
Then the doctor can increase the dose depending on your response.
Zdravnik lahko odmerek nato glede na odziv bolnika poveča.
You can turn the black dose knob backwards until the correct number appears in the LCD.
O: Da. Črni odmerni gumb lahko zasučete nazaj, dokler se na prikazovalniku LCD ne pojavi pravo število.
Tissue Growth
Tkivna rast
It should only be used to estimate the dosage remaining in the cartridge.
Namenjena je samo za oceno preostale količine v vložku.
System Organ Class Reactions observed in Pivotal and Supportive Clinical Trials (in 642 patients)
Organski sistem Neželeni učinki, opaženi v ključnih in podpornih kliničnih preskušanjih (pri 642 bolnikih)
For 51 patients who achieved near-adult height after an average duration of treatment of 6 years in males and 5 years in females, the mean near-adult height SDS was -0.7 in males and -1.2 in females.
Pri 51 bolnikih, ki so po povprečnem trajanju zdravljenja 6 let pri moških in 5 let pri ženskah dosegli skoraj odraslo telesno višino, je srednja vrednost SDS skoraj odrasle telesne višine znašala -0,7 pri moških in -1,2 pri ženskah.
In carcinogenicity studies testing biologically recombinant active growth hormone in rats and mice, no increase in the incidence of tumors was shown.
Pri študijah kancerogenosti pri biološkem testiranju aktivnega rekombinantnega rastnega hormona pri podganah in miših niso odkrili večje pojavnosti tumorjev.
In case of severe and persistent abdominal pain, consult your doctor.
V primeru pojava hude in trajne bolečine v trebuhu se posvetujte s svojim zdravnikom.
• If you accidentally touch the cartridge rubber seal, clean it with an alcohol swab.
• Če se po nesreči dotaknete gumijaste zapore, jo očistite z alkoholnim zložencem.
Always store your disposal container out of the reach of children.
Vsebnik za odstranjevanje vedno hranite nedosegljiv otrokom.
Supportive data are provided by two other studies, in which patients were given a dose of 0.3 or 0.6 mg/kg/week either as a daily injection or three times per week, or 0.029 mg/kg/day.
Na voljo so podporni podatki iz dveh drugih študij, v katerih so bolniki prejemali odmerek 0,3 ali 0,6 mg/kg/teden, bodisi v obliki vsakodnevne injekcije bodisi v obliki injekcije trikrat na teden, ali odmerek 0,029 mg/kg/dan.
The pharmacokinetic properties of NutropinAq have only been investigated in healthy adult males.
Farmakokinetične lastnosti zdravila NutropinAq so bile raziskane samo pri zdravih odraslih moških.
Growth hormone deficiency should be confirmed appropriately prior to treatment.
Pomanjkanje rastnega hormona je treba pred zdravljenjem ustrezno potrditi.
Long-term treatment of monkeys during pregnancy and lactation and of newborn animals until adolescence, sexual maturity and reproduction did not indicate substantial disturbances of fertility, pregnancy, delivery, nursing or development of progeny.
Dolgotrajno zdravljenje opic med brejostjo in dojenjem in novorojenih živalih do adolescence, spolne zrelosti in razmnoževanja ni pokazalo znatnih motenj plodnosti, brejosti, poroda, dojenja ali razvoja potomstva.
If you inject too much NutropinAq over a long period of time (years), you may experience some overgrowth of parts of your body such as ears, nose, lips, tongue and cheekbone (gigantism and/or acromegaly).
Če ste uporabljali prevelik odmerek zdravila NutropinAq daljši čas (leta), se lahko pojavi določena prekomerna rast posameznih delov telesa, kot so ušesa, nos, ustnice, jezik in ličnice (gigantizem in/ali akromegalija).
Adults with growth hormone deficiency (n=127) Very common: paraesthesia.
Odrasli s pomanjkanjem rastnega hormona (n=127) Zelo pogosti: parestezija.
The recommended final dose seldom exceeds 1.0 mg/day.
Priporočeni končni odmerek redko presega 1,0 mg/dan.
If you attempt to dose more than 4 mg at a time, the medicine will either be forced out of the needle and wasted or excess pressure will be placed upon the cartridge and it may crack.
Če poskusite naenkrat injicirati več kot 4 mg, bo zdravilo bodisi steklo iz igle in šlo v nič bodisi bo vložek deležen prevelikega pritiska in lahko poči.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
VSEBNOST IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
NutropinAq is a solution for injection (in a cartridge (10 mg/2 ml) - pack size of 1, 3 and 6).
Zdravilo NutropinAq je raztopina za injiciranje (v vložku (10 mg/2 ml) - pakiranja po 1, 3 in 6).
Then, start a new cartridge (as described in Part I) to administer the remaining portion of your medication.
V drugem primeru potem načnite nov vložek (kot je opisano v I. delu), da boste injicirali preostanek odmerka zdravila.
After removal from the refrigerator, if the solution is cloudy, the content must not be injected.
Če je raztopina, ko jo vzamete iz hladilnika, motna, vsebine ne smete injicirati.
• When your body does not make enough growth hormone and for this reason you are not growing properly.
• če telo ne tvori dovolj rastnega hormona in zato otrok ne raste pravilno.
Animal studies with somatropin showed that growth hormone localises to highly perfused organs, particularly the liver and kidney.
Študije na živalih s somatropinom so pokazale, da se rastni hormon lokalizira v močno prekrvljenih organih, posebno v jetrih in ledvicah.
Both studies demonstrated a statistically significant increase in growth rate compared to placebo over the first year (9.1-10.9 cm/year vs 6.2-6.6 cm/year), which decreased slightly in the second year (7.4-7.9 cm/year vs 5.5-6.6 cm/year).
Obe študiji sta pokazali statistično pomembno povečanje stopnje rasti v primerjavi s placebom v prvem letu (9,1-10,9 cm/leto v primerjavi s 6,2-6,6 cm/leto), ki se je nekoliko zmanjšala v drugem letu (7,4-7,9 cm/leto v primerjavi s 5,5-6,6 cm/leto).
The most serious adverse reactions from the pivotal and supportive clinical trials were neoplasm and intracranial hypertension.
Najresnejši neželeni učinki v ključnih in podpornih kliničnih preskušanjih so bile novotvorbe in intrakranialna hipertenzija.
It is typically associated with papilloedema, visual changes, headache, nausea, and/or vomiting and symptoms usually occur within eight weeks of initiation of therapy with NutropinAq.
Običajno je bila povezana s papiledemom, spremembami vida, glavobolom, navzeo in/ali bruhanjem, simptomi pa so se običajno pojavili v osmih tednih po uvedbi zdravljenja z zdravilom NutropinAq.
The final dose is rarely above 1.0 mg/day.
Končni odmerek je redko večji od 1,0 mg/dan.
The dose of NutropinAq to be injected will be decided by your doctor.
Odmerek zdravila NutropinAq, ki ga boste injicirali, bo določil zdravnik.
Girls with Turner syndrome commonly reported abnormally heavy bleeding at menstruation.
Pri deklicah s Turnerjevim sindromom so pogosto poročali o nenormalno močnih menstruacijskih krvavitvah.
Return the cartridge to your pharmacist or prescribing doctor.
Vložek vrnite svojemu farmacevtu ali zdravniku, ki ga je predpisal.
For subsequent injections with the NutropinAq Pen, attach a new needle, push the white reset button and dial your dose.
Za nadaljnje injekcije z injekcijskim peresnikom NutropinAq Pen namestite novo iglo, pritisnite beli nastavitveni gumb in nastavite svoj odmerek.
Wipe the rubber seal of the NutropinAq with rubbing alcohol or an antiseptic solution to prevent contamination of the contents by microorganisms that may be introduced by repeated needle insertions.
Obrišite gumijasto zaporo vložka zdravila NutropinAq z alkoholom ali antiseptično raztopino, da boste preprečili kontaminacijo vsebine z mikroorganizmi, do česar bi lahko prišlo zaradi večkratnega zabadanja injekcijske igle.
For each injection you should use a new sterile injection needle.
Pri vsakem injiciranju morate uporabiti novo sterilno injekcijsko iglo.
Girls with growth failure associated with Turner syndrome (n=108) Common: menorrhagia.
Deklice z zaostankom v rasti, povezanim s Turnerjevim sindromom (n=108) Pogosti: menoragija.
A: The NutropinAq Pen is designed to last 24 months from the time you first use your pen.
O: Injekcijski peresnik NutropinAq Pen je zasnovan tako, da se lahko uporablja 24 mesecev od prve uporabe.
NutropinAq is not indicated for the long-term treatment of paediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome, unless they also have a diagnosis of growth hormone deficiency.
Zdravilo NutropinAq ni indicirano za dolgotrajno zdravljenje pri pediatričnih bolnikih z zaostankom v rasti zaradi genetsko potrjenega Prader-Willijevega sindroma, razen če imajo ti bolniki tudi diagnozo pomanjkanja rastnega hormona.
• The NutropinAq cartridge may be used for up to 28 days.
• Vložek zdravila NutropinAq smete uporabljati največ 28 dni.
Reduced ability to absorb sugar (glucose) from your blood leading to high blood sugar levels (hyperglycemia).
Zmanjšana sposobnost za absorpcijo sladkorja (glukoze) iz krvi, kar vodi do visoke ravni krvnega sladkorja (hiperglikemija).
Acute overdose could lead to hyperglycaemia.
Akutno preveliko odmerjanje lahko povzroči hiperglikemijo.
Increased heart rate (tachycardia) and high blood pressure (hypertension).
Zvečan srčni utrip (tahikardija) in visok krvni tlak (hipertenzija).
No significant changes in bone mineral density (BMD) were observed in adult-onset AGHD patients, however in the childhood-onset study, all groups had an increase in BMD at 24 months, although there was no statistically significant dose response for total body BMD.
Pri odraslih bolnikih s pomanjkanjem rastnega hormona z začetkom v odrasli dobi niso opazili pomembnih sprememb mineralne gostote kosti (BMD- bone mineral density), v študiji z začetkom pomanjkanja v otroštvu pa so vse skupine imele večje BMD v 24. mesecu, čeprav ni bilo statistično pomembnega odziva na odmerek za BMD celotnega telesa.
Growth hormone is filtered at the glomerulus and reabsorbed in the proximal tubules.
Rastni hormon se filtrira v glomerulih in reabsorbira v proksimalnih tubulih.
What NutropinAq is and what it is used for
Kaj je zdravilo NutropinAq in za kaj ga uporabljamo
The effect of NutropinAq has not been assessed in conventional animal fertility studies (see section 5.3) or clinical studies.
Učinkov zdravila NutropinAq v običajnih študijah plodnosti pri živalih (glejte poglavje 5.3) ali v kliničnih študijah niso vrednotili.
Do not use this medicine after the expiry date which is stated on the label of the cartridge and the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki na vložku in škatli poleg oznake “EXP” ali “Uporabno do”.
It is recombinant, meaning it is made outside of the body by a special process.
Somatropin je pridobljen z genskim inženirstvom, kar pomeni, da je s posebnim postopkom pridobljen zunaj telesa.
In adults, it helps to maintain normal body shape and metabolism for example lipid profile and glucose levels.
Pri odraslih zdravilo omogoča vzdrževati normalno obliko telesa in presnovo, na primer lipidni profil in vrednosti glukoze.
If no drop of medicine appears, push the white reset button again.
Če se kapljica zdravila ne pojavi, znova pritisnite beli nastavitveni gumb.
A: To maintain its strength.
O: Za ohranitev jakosti zdravila.
Animal studies suggest that the kidney is the dominant organ of clearance.
Študije na živalih kažejo, da so glavni organ izločanja ledvice.
Twist off the needle and discard it properly.
Iglo odvijte in jo pravilno zavrzite.
After subcutaneous bolus administration, the mean terminal half-life t½ of somatropin is about 2.3 hours.
Po subkutani bolusni aplikaciji je povprečni končni razpolovni čas t½ somatropina približno 2,3 ure.
In children with chronic renal insufficiency:
Otroci s kronično ledvično insuficienco:
In both studies, somatropin treatment resulted in significant changes compared to placebo in total body % fat (-6.3 to -3.6 vs +0.2 to-0.1), trunk % fat (-7.6 to -4.3 vs +0.6 to 0.0) and total body % lean (+3.6 to +6.4 vs -0.2 to +0.2).
V obeh študijah je pri zdravljenju s somatropinom prišlo do pomembnih sprememb v primerjavi s placebom v % skupnega telesnega maščevja (-6,3 do -3,6 v primerjavi z +0,2 do -0,1), % maščevja na trupu (-7,6 do -4,3 v primerjavi s +0,6 do 0.0) in % skupne puste telesne mase (+3,6 do +6,4 v primerjavi z -0,2 do +0,2).
Compared with matched historical controls, early somatropin therapy (mean duration of 5.6 years) combined with oestrogen replacement at age 12 years resulted in an adult height gain of 5.9 cm (n=26), whereas girls who initiated oestrogen at age 15 years (mean duration of somatropin therapy 6.1 years) had a mean adult height gain of 8.3 cm (n=29).
V primerjavi z ustreznimi historičnimi kontrolami, je bilo zgodnje zdravljenje s somatropinom (povprečno trajanje 5,6 let) v kombinaciji z nadomeščanjem estrogena pri starosti 12 let, povezano s pridobitvijo telesne višine v odrasli dobi za 5,9 cm (n=26), medtem ko so dekleta, ki so začela zdravljenje z estrogenom pri starosti 15 let (srednje trajanje zdravljenja s somatropinom 6,1 let), imele povprečni prirastek telesne višine v odrasli dobi 8,3 cm (n=29).
Toxicity to reproduction and development
Škodljivi vplivi na razmnoževanje in razvoj
Sensitive and dry skin (exfoliative dermatitis), changes in thickness of the skin, excessive growth of hair on the face and body (hirsutism), hives (urticaria).
Občutljiva in suha koža (eksfoliativni dermatitis), spremembe v debelini kože, prekomerna rast dlak na obrazu in telesu pri ženskah (hirzutizem) in koprivnica (urtikarija).
Tell your doctor immediately if you experience visual changes, bad or frequent headaches, associated with feeling sick (nausea) or vomiting.
Nemudoma obvestite svojega zdravnika, če opazite spremembe vida, hude ali pogoste glavobole, ki so povezani s siljenjem na bruhanje (navzea) ali z bruhanjem.
In total, 128 patients received somatropin over the 24 month controlled phase of the 2 studies, and 139 patients were treated with somatropin in the open extension phases.
V 24-mesečni nadzorovani fazi dveh študij je somatropin prejemalo 128 bolnikov, v odprti podaljšani fazi pa se je s somatropinom zdravilo 139 bolnikov.
NutropinAq therapy should be carried out under regular guidance of a doctor who is experienced in growth hormone deficiency.
Zdravljenje z zdravilom NutropinAq mora potekati pod rednim nadzorom zdravnika, ki ima izkušnje z zdravljenjem pomanjkanja rastnega hormona.
Test for growth hormone deficiency should not be performed until adequate replacement therapy for other hormone deficiencies have been instituted.
Preiskave za pomanjkanje rastnega hormona se ne sme opraviti pred začetkom ustreznega nadomestnega zdravljenja drugih hormonskih pomanjkanj.
Common: Drug specific antibody present
Pogosti: prisotnost specifičnih protiteles proti zdravilu
You have to inject NutropinAq every day under the skin (subcutaneous injection).
Zdravilo NutropinAq morate vsak dan injicirati pod kožo (subkutana injekcija).
- Long-term treatment of girls from 2 years old with growth failure associated with Turner syndrome.
- Dolgotrajno zdravljenje zaostanka v rasti pri deklicah, starejših od 2 let, povezanega s Turnerjevim sindromom.
Change the injection sites to avoid discomfort.
Mesta injiciranja krožno menjavajte, da boste preprečili neprijetnosti.
At the start of therapy, it is recommended that a doctor or a nurse give you the injection and train you with the NutropinAq Pen.
Na začetku zdravljenja je priporočljivo, da vam injekcijo da zdravnik ali medicinska sestra in vas nauči pravilne uporabe injekcijskega peresnika NutropinAq Pen.
For in-use storage conditions of the medicinal product, see section 6.3.
Za pogoje shranjevanja med uporabo zdravila glejte poglavje 6.3.
• If you notice a curve of your spine (scoliosis) you will need to be checked often by your doctor as scoliosis may progress in any child during rapid growth.
• Če opazite ukrivljenost hrbtenice (skolioza), bodo potrebni pogostejši pregledi pri zdravniku, saj lahko skolioza napreduje pri vsakem otroku v obdobju hitre rasti.
• If your body does not make enough growth hormone as an adult.
• če telo ne tvori dovolj rastnega hormona v odrasli dobi.
Reported values for half-lives for endogenous GH in normal adult black males are not different from observed values for normal adult white males.
Vrednosti razpolovnega časa endogenega rastnega hormona pri normalnih odraslih moških črne rase se ne razlikujejo od vrednosti pri normalnih odraslih moških bele rase.
Actions that have been demonstrated for human growth hormone include:
Med dokazanimi učinki humanega rastnega hormona so:
Other medicines and NutropinAq
Druga zdravila in zdravilo NutropinAq
Only use the pen needles recommended by your doctor or nurse.
Uporabljajte le tiste igle za injekcijski peresnik, ki vam jih svetuje zdravnik ali medicinska sestra.
After this training, you will be able to inject yourself or be injected by a trained care-giver.
Po ustreznem usposabljanju si lahko zdravilo injicirate sami ali pa vam ga injicira oseba, ki skrbi za vas.
Pull the needle shield off the pen (if you have used one) and place the larger needle cap on a flat surface.
Potegnite ščitnik igle iz injekcijskega peresnika (če ste ga uporabili) in položite večji pokrovček igle na ravno površino.
This side effect is rare, it may affect up to 1 in 1,000 patients.
Ta neželeni učinek je redek, pojavi se lahko pri do 1 od 1.000 bolnikov.
Inspect all new cartridges prior to use.
Vse nove vložke pred uporabo preglejte.
The underlying risk varies according to the underlying cause for growth hormone deficiency (e.g. secondary to intracranial lesion), associated co- morbidities and treatment(s) undertaken.
Osnovno tveganje se razlikuje glede na osnovni vzrok za pomanjkanje rastnega hormona (npr. sekundarno po intrakranialni leziji), povezavo s sočasnimi obolenji in zdravljenjem.
Limited published data indicate that growth hormone treatment increases cytochrome P450 mediated antipyrine clearance in man.
Omejeni objavljeni podatki kažejo, da zdravljenje z rastnim hormonom pri človeku zveča s citokromom P450 posredovani očistek antipirina.
• if you are treated with sex steroids, anticonvulsants or cyclosporin ask the doctor for advice.
• Če se zdravite s spolnimi steroidi, z antiepileptiki ali s ciklosporinom, se posvetujte s svojim zdravnikom.
If you have injected more NutropinAq than you should have, contact your doctor for advice.
Če ste si injicirali večji odmerek zdravila NutropinAq, kot bi smeli, se posvetujte s svojim zdravnikom.
In vitro and in vivo preclinical and clinical tests have demonstrated that somatropin is therapeutically equivalent to human growth hormone of pituitary origin.
Predklinične in klinične raziskave in vitro in in vivo so pokazale, da je somatropin terapevtsko enakovreden humanemu rastnemu hormonu hipofiznega izvora.
Pharmacotherapeutic group: Pituitary and hypothalamic hormones and analogues, Somatropin and analogues, ATC Code: H01 AC 01
Farmakoterapevtska skupina: Hipofizni in hipotalamični hormoni ter sorodne učinkovine, somatropin in sorodne učinkovine, oznaka ATC: H01AC01
If you have intracranial hypertension, your doctor may decide to temporarily reduce or discontinue NutropinAq therapy.
Če imate intrakranialno hipertenzijo, lahko zdravnik začasno zmanjša odmerek zdravila NutropinAq ali zdravljenje prekine.
If you inject too much NutropinAq, your blood sugar level may decrease and become too low and then rise too high (hyperglycaemia).
Če ste si injicirali prevelik odmerek zdravila NutropinAq, se lahko koncentracija krvnega sladkorja zmanjša in postane prenizka, nato pa prekomerno naraste (hiperglikemija).